1. Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects
   Ravi Kumar Paluri et al, 2023, Oncology Reviews CrossRef
2. Influence of Antibiotic Use on the Effectiveness and Safety of Immune Checkpoint Inhibitors
   Takuya Minamishima et al, 2022, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) CrossRef
3. Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine
   Evan R. Barry et al, 2021, Cells CrossRef
4. Survival Benefit of Statin with Anti-Angiogenesis Efficacy in Lung Cancer-Associated Pleural Fluid through FXR Modulation
   Chen-Liang Tsai et al, 2022, Cancers CrossRef
5. Phenolic diterpenes from Rosemary supercritical extract inhibit non-small cell lung cancer lipid metabolism and synergise with therapeutic drugs in the clinic
   Adrián Bouzas et al, 2022, Frontiers in Oncology CrossRef
6. Tumor immune microenvironment modulation by cholesterol in hepatocellular carcinoma
   Alejandro Escobedo-Calvario et al, 2022, Exploration of Digestive Diseases CrossRef
7. Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment
   Jingtao Tong et al, 2021, Cancer Management and Research CrossRef
8. Cholesterol Metabolism as a Potential Therapeutic Target and a Prognostic Biomarker for Cancer Immunotherapy
   Huixian Zhang et al, 2021, OncoTargets and Therapy CrossRef
9. Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling
   Woo-Jin Lim et al, 2021, Cells CrossRef
10. Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
    Ana Callejo et al, 2021, Cancers CrossRef
11. Heterogeneity of glioblastoma stem cells in the context of the immune microenvironment and geospatial organization
    Aryeh Silver et al, 2022, Frontiers in Oncology CrossRef
12. A Forgotten Corner in Cancer Immunotherapy: The Role of Lipids
    Yang Yu et al, 2021, Frontiers in Oncology CrossRef
13. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients
    Luca Cantini et al, 2021, European Journal of Cancer CrossRef
14. Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
    Toshiki Ogiwara et al, 2021, Frontiers in Oncology CrossRef
15. Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations
    Xiangbing Meng et al, 2021, Frontiers in Medicine CrossRef
16. Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis
    Lei Zhang et al, 2022, International Journal of Clinical Practice CrossRef
17. Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
    Tove Selvin et al, 2023, BMC Cancer CrossRef
18. Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
    Tove Selvin et al, 2024, BMC Pharmacology and Toxicology CrossRef
19. Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells
    Thuzar Hla Shwe et al, 2021, International Journal of Molecular Sciences CrossRef